Developing treatments for the diseases that are hardest to treat*

We wholly own a platform with the potential for treating a wide range of diseases — from cancers to inflammation-based diseases like arthritis and kidney disease. Endocyte technology is in late-stage clinical trials and is under review for conditional approval in Europe.

PLATFORM YIELDS MULTIPLE NEW SMDCs*

PROGRAM / INDICATION PHASE DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PENDING
APPROVAL
ONCOLOGY – FOLATE RECEPTOR
Vynfinit® (Folate-DAVLBH)
Platinum Resistant Ovarian Cancer PENDING APPROVAL            
Non-small Cell Lung Cancer PHASE 2            
Triple Negative Breast Cancer PHASE 2            
Carboplatin/Paclitaxel Combination PHASE 1            
EC1456 (Folate-Tubulysin)
Solid Tumors PHASE 1            
EC1788 (Folate-DNA alkylator)
Solid Tumors PRECLINICAL            
Folcepri® (Folate-Tc99m)
Folate Receptor Positive Tumors PENDING APPROVAL            
ONCOLOGY – PROSTATE SPECIFIC MEMBRANE ANTIGEN
EC1169 (PSMA-Tubulysin)
Prostate Cancer PHASE 1            
EC0652 (PSMA-Tc99m)
Prostate Tumors PHASE 1            
INFLAMMATION – FOLATE RECEPTOR
EC1669 (Folate-Aminopterin)
Inflammation PRECLINICAL            
KIDNEY – FOLATE INHIBITOR
EC0371 (Folate-mTor Inhibitor)
Polycystic Kidney Disease PRECLINICAL            

 SMDC  Companion Imaging Diagnostic

Endocyte technology has the potential for broad application

Our technology has the potential to treat the types of cancers found in over 40% of cancer patients worldwide.1 Our lead companion imaging agent and SMDC target the folate receptor, which is frequently expressed in some of the most prevalent, and difficult to treat, solid tumor cancer indications, including non-small cell lung, breast, colorectal, kidney, endometrial, and ovarian cancers.

Using our flexible SMDC technology platform, we are also developing precision therapies for other cancer-cell receptors and diseases. One of our imaging agents, EC0652, is being developed to non-invasively identify tumors that overexpress prostate-specific membrane antigen (PSMA) receptors, and is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer. 

An engine for new drug development

With the advent of an innovative form of delivery, more research and development can focus on new potent cytotoxic drugs.

What’s more, our modular technology is being studied with different drugs or a combination of drugs in a variety of diseases, allowing for potential expansion into lower-expressing cancer indications and other difficult-to-treat diseases.

Our pipeline and the future of precision medicine

Three new SMDCs are now entering clinical trials: one is a prostate-specific membrane antigen (PSMA)-targeted drug, another is a candidate for inflammation indication, and the third is designed to deliver a potent chemotherapy drug called tubulysin using our second-generation guidance system. 

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

1. Reference: Low PS, Klaratne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009 Jun;13(3):256-262. doi: 10.1016/j.cbpa.2009.03.022. Epub 2009 May 4.